scholarly journals Non-reactor neutron sources for BNCT (Boron Neutron Capture Therapy)

1989 ◽  
Author(s):  
T. Dolan ◽  
E. Ottewitte ◽  
E. Wills ◽  
W. Neuman ◽  
D. Woodall
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Reactor Neutron ◽  
Neutron Capture Therapy ◽  
Neutron Sources ◽  
Boron Neutron Capture

Carboxyboranylamino ethanol: Unprecedented discovery of boron agent for neutron capture therapy in cancer treatment

2021 ◽  
Author(s):  
Yinghuai Zhu ◽  
Jianghong Cai ◽  
Narayan S Hosmane ◽  
Minoru Suzuki ◽  
Kazuko Uno ◽  
...  
Keyword(s):  
Pharmaceutical Industry ◽  
Cancer Treatment ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Neutron Sources ◽  
Boron Neutron Capture

Following the latest development and popularization of the neutron sources, boron neutron capture therapy (BNCT) has re-attracted great efforts and interest from both academia and pharmaceutical industry. The FDA approved...

scholarly journals CYTOPATHIC EFFECTS OF ACCELERATOR-BASED BORON NEUTRON CAPTURE THERAPY ON HUMAN GLIOBLASTOMA CELLS

2019 ◽  
Vol 18 (4) ◽  
pp. 34-42
Author(s):  
V. A. Byvaltsev ◽  
E. L. Zavjalov ◽  
V. V. Kanygin ◽  
A. I. Kasatova ◽  
A. I. Kichigin ◽  
...  
Keyword(s):  
Cell Line ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Boron Concentration ◽  
Neutron Capture Therapy ◽  
Neutron Sources ◽  
Cytopathic Effects ◽  
Boron Neutron Capture ◽  
Colony Forming Assay ◽  
U87 Cells

Boron neutron capture therapy (BNCT) is a targeted therapy based on a selective damage to cancer cells due to the interaction between boron-10 isotope and neutron. Reactor-based BNCT has been found to be effective in the treatment of high-grade gliomas. It is believed that compact accelerator-based neutron sources will ensure widespread adoption of the technique in clinical practice. New accelerator-based neutron sources are being actively developed all over the world. At the Institute of Nuclear Physics (Russia), the accelerator-based neutron source was developed for pre-clinical studies of BNCT.Purpose: to determine the cytopathic effects of accelerator-based BNCT on the human U87-glioblastoma cell line and to select a concentration of boron drugs that do not have a toxic effect on the cells before irradiation in vitro.Material and Methods. To assess the cytopathic effects (MTT test and colony-forming assay) of various concentrations of boron-containing drugs, U87 cells were incubated with boronophenylalanine (BPA) and sodium borocaptate (BSH) for 1, 2 and 10 days. The effect of BNCT on the U87 cell line was determined using colony-forming assay.Results. The MTT test showed a decrease in cell survival at a boron-10 isotope concentration of 160 μg/ml after 48 hours and 640 μg/ml after 24 hours of incubation for BPA. The cytopathic effects for sodium BSH appeared at a boron concentration of 80 µg / ml after 48 hours of incubation, and survival fraction of cells was reduced to 89 % compared to the control. According to the colonyforming assay, the cytotoxic effects of BSH and BPA at a boron concentration of 40 µg/ml in the medium were 79.6 and 84 %, respectively. The proportions of surviving cells were 18 ± 2 % and 13 ± 2 % after epithermal neutron irradiation in the presence of boronophenylalanine and in the presence of sodium borocaptate, respectively. Cell death without boron drugs occurred due to the neutron elastic scattering, nuclear reactions of thermal neutron capture by hydrogen and nitrogen, and accompanying gamma radiation.Conclusion. The study clearly showed a decrease in the proportion of surviving U87 cells after accelerator-based BNCT in the presence of 10B-enriched BSH and BPA. 

scholarly journals The basis and advances in clinical application of boron neutron capture therapy

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Huifang He ◽  
Jiyuan Li ◽  
Ping Jiang ◽  
Suqing Tian ◽  
Hao Wang ◽  
...  
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Radiation Oncology ◽  
Neutron Capture ◽  
Normal Tissue ◽  
Neutron Capture Therapy ◽  
Thermal Neutrons ◽  
Neutron Sources ◽  
Boron Neutron Capture ◽  
High Linear Energy Transfer ◽  
Α Particles

AbstractBoron neutron capture therapy (BNCT) was first proposed as early as 1936, and research on BNCT has progressed relatively slowly but steadily. BNCT is a potentially useful tool for cancer treatment that selectively damages cancer cells while sparing normal tissue. BNCT is based on the nuclear reaction that occurs when 10B capture low-energy thermal neutrons to yield high-linear energy transfer (LET) α particles and recoiling 7Li nuclei. A large number of 10B atoms have to be localized within the tumor cells for BNCT to be effective, and an adequate number of thermal neutrons need to be absorbed by the 10B atoms to generate lethal 10B (n, α)7Li reactions. Effective boron neutron capture therapy cannot be achieved without appropriate boron carriers. Improvement in boron delivery and the development of the best dosing paradigms for both boronophenylalanine (BPA) and sodium borocaptate (BSH) are of major importance, yet these still have not been optimized. Here, we present a review of this treatment modality from the perspectives of radiation oncology, biology, and physics. This manuscript provides a brief introduction of the mechanism of cancer-cell-selective killing by BNCT, radiobiological factors, and progress in the development of boron carriers and neutron sources as well as the results of clinical study.

scholarly journals HGG-05. REGRESSION OF RECURRENT GLIOBLASTOMA AFTER BORON NEUTRON CAPTURE THERAPY AND CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN A CHILD

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii345-iii345
Author(s):  
Hsin-Hung Chen ◽  
Yi-Wei Chen
Keyword(s):  
T Cells ◽  
T Cell ◽  
Chimeric Antigen Receptor ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Antigen Receptor ◽  
Neutron Capture Therapy ◽  
T Cell Therapy ◽  
Boron Neutron Capture ◽  
Car T

Abstract A 6 y/o girl with recurrent multifocal glioblastoma received 3 times of boron neutron capture therapy (BNCT) and chimeric antigen receptor (CAR)–engineered T cells targeting the tumor-associated antigen HER2. Multiple infusions of CAR T cells were administered over 30 days through intraventricular delivery routes. It was not associated with any toxic effects of grade 3 or higher. After BNCT and CAR T-cell treatment, regression of all existing intracranial lesions were observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid, but new lesions recurred soon after the treatment. This clinical response continued for 14 months after the initiation of first recurrence.

Sign in / Sign up

Export Citation Format

Share Document